Business
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company’s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA.\n\n\nDetails of the presentations are as follows:\n\n\nPoster Number: 573\nAbstract Number: 2257506\nTitle: Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities\nDate: Thursday, April 16, 2026\nTime: 11:30 AM – 12:30 PM ET\nSession Type: Therapeutic Approaches to Autoimmunity (THER)\nSession Title: Therapeutics for Autoimmune Diseases I\nLocation: Exhibit Hall\nPresenter: Jonathan Kibel and Meng Huang, Ph.D.\n\n\nPoster Number: 193\nAbstract Number: 2253997\nTitle: EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model\nDate: Friday, April 17, 2026\nTime: 11:30 AM – 12:30 PM ET\nSession Type: Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)\nSession Title: Airway Hypersensitivity and Asthma\nLocation: Exhibit Hall\nPresenter: Yaohui Nie, Ph.D.\n\n\nPoster Number: 194\nAbstract Number: 2257118\nTitle: Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases\nDate: Friday, April 17, 2026\nTime: 2:30 – 3:30 PM ET\nSession Type: Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)\nSession Title: Airway Hypersensitivity and Asthma\nLocation: Exhibit Hall\nPresenter: Joyce Sweeney Gibbons, Ph.D.\n\n\nPoster Number: 723\nAbstract Number: 2257175\nTitle: Potent STAT6 Inhibitor EPS-3903 Demonstrates Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition following Once-Daily Oral Dosing in Humans\nDate Saturday, April 18, 2026\nTime: 11:30 AM – 12:30 PM ET\nSession Type: Therapeutic Approaches to Autoimmunity (THER)\nSession Title: Therapeutics for Autoimmune Diseases I\nLocation: Exhibit Hall\nPresenter: Daniel Leonard and Tianzhu Zang, Ph.D.\n\n\nFurther information about IMMUNOLOGY2026TM can be found here. Posters will be...